Inhibition of 37/67kDa Laminin-1 Receptor Restores APP Maturation and Reduces Amyloid-β in Human Skin Fibroblasts from Familial Alzheimer’s Disease

Alzheimer’s disease (AD) is a fatal neurodegenerative disorder caused by protein misfolding and aggregation, affecting brain function and causing dementia. Amyloid beta (Aβ), a peptide deriving from amyloid precursor protein (APP) cleavage by-and γ-secretases, is considered a pathological hallmark of AD. Our previous study, together with several lines of evidence, identified a strict link between APP, Aβ and 37/67kDa laminin receptor (LR), finding the possibility to regulate intracellular APP localization and maturation through modulation of the receptor. Here, we report that in fibroblasts from familial AD (fAD), APP was prevalently expressed as an immature isoform and accumulated preferentially in the transferrin-positive recycling compartment rather than in the Golgi apparatus. Moreover, besides the altered mitochondrial network exhibited by fAD patient cells, the levels of pAkt and pGSK3 were reduced in respect to healthy control fibroblasts and were accompanied by an increased amount of secreted Aβ in conditioned medium from cell cultures. Interestingly, these features were reversed by inhibition of 37/67kDa LR by NSC47924 a small molecule that was able to rescue the “typical” APP localization in the Golgi apparatus, with consequences on the Aβ level and mitochondrial network. Altogether, these findings suggest that 37/67kDa LR modulation may represent a useful tool to control APP trafficking and Aβ levels with implications in Alzheimer’s disease.

[1]  L. Buée,et al.  Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains , 2020, Acta Neuropathologica.

[2]  A. Conti,et al.  Targeting Mitochondrial Network Architecture in Down Syndrome and Aging , 2020, International journal of molecular sciences.

[3]  V. D’Argenio,et al.  New Insights into the Molecular Bases of Familial Alzheimer’s Disease , 2020, Journal of personalized medicine.

[4]  A. Lavecchia,et al.  APP Maturation and Intracellular Localization Are Controlled by a Specific Inhibitor of 37/67 kDa Laminin-1 Receptor in Neuronal Cells , 2020, International journal of molecular sciences.

[5]  F. Perez,et al.  Distinct anterograde trafficking pathways of BACE1 and amyloid precursor protein from the TGN and the regulation of amyloid-β production , 2019, Molecular biology of the cell.

[6]  V. D’Argenio,et al.  Microbiome Influence in the Pathogenesis of Prion and Alzheimer’s Diseases , 2019, International journal of molecular sciences.

[7]  G. Cenini,et al.  Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update , 2019, Front. Pharmacol..

[8]  P. Gleeson,et al.  The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease. , 2019, Biochimica et biophysica acta. Biomembranes.

[9]  P. Gleeson,et al.  The trans-Golgi network is a major site for α-secretase processing of amyloid precursor protein in primary neurons , 2018, The Journal of Biological Chemistry.

[10]  D. Sarnataro,et al.  Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases , 2018, International journal of molecular sciences.

[11]  Xian-Zhen Deng,et al.  The Fate of Nascent APP in Hippocampal Neurons: A Live Cell Imaging Study. , 2018, ACS chemical neuroscience.

[12]  Linfu Li,et al.  The Key Roles of GSK-3β in Regulating Mitochondrial Activity , 2017, Cellular Physiology and Biochemistry.

[13]  Anna Ochałek,et al.  Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation , 2017, Alzheimer's Research & Therapy.

[14]  Sangyun Jeong,et al.  Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease , 2017, Molecules and cells.

[15]  Weihong Song,et al.  Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease , 2017, Front. Mol. Neurosci..

[16]  F. Esposito,et al.  Regulation of sub-compartmental targeting and folding properties of the Prion-like protein Shadoo , 2017, Scientific Reports.

[17]  C. Procaccini,et al.  Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells , 2017, Human molecular genetics.

[18]  F. Checler,et al.  Localization and Processing of the Amyloid-β Protein Precursor in Mitochondria-Associated Membranes , 2016, Journal of Alzheimer's disease : JAD.

[19]  R. Scarpulla,et al.  Concerted Action of PGC-1-related Coactivator (PRC) and c-MYC in the Stress Response to Mitochondrial Dysfunction* , 2016, The Journal of Biological Chemistry.

[20]  P. Gleeson,et al.  Dysregulation of intracellular trafficking and endosomal sorting in Alzheimer's disease: controversies and unanswered questions. , 2016, The Biochemical journal.

[21]  C. Broeckhoven,et al.  Molecular genetics of early-onset Alzheimer's disease revisited , 2016, Alzheimer's & Dementia.

[22]  A. Lavecchia,et al.  The 37/67kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67kDa LR cell surface localization and interaction with the cellular prion protein , 2016, Scientific Reports.

[23]  M. Little,et al.  LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[24]  A. Lavecchia,et al.  Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion , 2015, Oncotarget.

[25]  Eloise Ferreira,et al.  Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer’s disease , 2015, Expert opinion on therapeutic patents.

[26]  A. Zagari,et al.  Membrane protein 4F2/CD98 is a cell surface receptor involved in the internalization and trafficking of human β-Defensin 3 in epithelial cells. , 2015, Chemistry & biology.

[27]  C. Seah,et al.  The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid , 2014, Molecular Brain.

[28]  M. Little,et al.  The 37kDa/67kDa Laminin Receptor acts as a receptor for Aβ42 internalization , 2014, Scientific Reports.

[29]  B. Loos,et al.  High Resolution Imaging Study of Interactions between the 37 kDa/67 kDa Laminin Receptor and APP, Beta-Secretase and Gamma-Secretase in Alzheimer's Disease , 2014, PloS one.

[30]  V. Boddi,et al.  Altered Proteolysis in Fibroblasts of Alzheimer Patients with Predictive Implications for Subjects at Risk of Disease , 2014, International journal of Alzheimer's disease.

[31]  E. Koo,et al.  Activity-Induced Convergence of APP and BACE-1 in Acidic Microdomains via an Endocytosis-Dependent Pathway , 2013, Neuron.

[32]  D. Chan Fusion and fission: interlinked processes critical for mitochondrial health. , 2012, Annual review of genetics.

[33]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[34]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[35]  P. Reddy,et al.  Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. , 2011, Human molecular genetics.

[36]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[38]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[39]  A. Sporbert,et al.  SorLA/LR11 Regulates Processing of Amyloid Precursor Protein via Interaction with Adaptors GGA and PACS-1* , 2007, Journal of Biological Chemistry.

[40]  H. Anandatheerthavarada,et al.  Amyloid Precursor Protein and Mitochondrial Dysfunction in Alzheimer's Disease , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[41]  K. Leroy,et al.  Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration , 2007, Neuropathology and applied neurobiology.

[42]  F. Cordelières,et al.  A guided tour into subcellular colocalization analysis in light microscopy , 2006, Journal of microscopy.

[43]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Robert S. Balaban,et al.  Mitochondria, Oxidants, and Aging , 2005, Cell.

[45]  Anthony Holland,et al.  Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain , 2004, The European journal of neuroscience.

[46]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[47]  D. Teplow,et al.  Apical Sorting of β-Secretase Limits Amyloid β-Peptide Production* , 2002, The Journal of Biological Chemistry.

[48]  A. Nunomura,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[49]  H. Braak,et al.  Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes , 1999 .

[50]  G. P. Connolly Fibroblast models of neurological disorders: fluorescence measurement studies. , 1998, Trends in pharmacological sciences.

[51]  D. Alkon,et al.  Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  E. Braak,et al.  Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain , 1997, Journal of neuropathology and experimental neurology.

[53]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[54]  M. Trabucchi,et al.  Peripheral cells as an investigational tool for Alzheimer's disease. , 1996, Life sciences.

[55]  H. Wiśniewski,et al.  High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. , 1995, Neuroreport.

[56]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[57]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[58]  B. Winblad,et al.  Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  C. Zurzolo,et al.  Cell Biology of Prion Protein. , 2017, Progress in molecular biology and translational science.

[60]  D. Teplow,et al.  Apical sorting of beta-secretase limits amyloid beta-peptide production. , 2002, The Journal of biological chemistry.

[61]  C. Haass,et al.  Posttranslational modifications of amyloid precursor protein : ectodomain phosphorylation and sulfation. , 2000, Methods in molecular medicine.

[62]  H. Braak,et al.  Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. , 1999, Journal of neuropathology and experimental neurology.

[63]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.